Memorandum

TO: Regional Directors, Health Service Regions
Regional Immunization Program Managers, Health Service Regions
Health Department Directors, Local Health Departments
Immunization Program Managers, Local Health Departments

FROM: Karen Hess, Manager
Vaccine Services Group

THRU: Jack C. Sims, Manager
Immunization Branch

DATE: March 6, 2009

SUBJECT: Texas Vaccines for Children Program and Adult Safety Net Program: ACIP Provisional Recommendations for Use of Pneumococcal Vaccines

The Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) approved the expanded use of pneumococcal polysaccharide vaccine (PPSV23) on October 22, 2008. Effective immediately, the following recommendations should be used to determine who should receive this vaccine through both the Texas Vaccines for Children Program and the Department of State Health Services Adult Safety Net Program.

A summary of the ACIP-expanded recommended usage of PPSV23 is below:

1. Persons aged 19 through 64 years who smoke cigarettes should receive a single dose of PPSV23 and smoking cessation counseling.

2. Persons aged 19 through 64 years who have asthma should receive a single dose of PPSV23.

3. A second dose of PPSV23 is recommended 5 years after the first dose of PPSV23 for persons aged ≥2 years who are immunocompromised, have sickle cell disease, or functional or anatomic asplenia.
In addition, the ACIP has revised the recommendations for the use of PPSV23 among American Indians and Alaska Natives:

American Indian/Alaska Native children aged 24 through 59 months:

Routine use of PPSV23 after PCV7 is not recommended for American Indian or Alaska Native children aged 24 through 59 months. However, in special situations, public health authorities may recommend the use of PPSV23 after PCV7 for these children who are living in areas in which risk of invasive pneumococcal disease is increased.

American Indian/Alaska Native adults:

Routine use of PPSV23 is not recommended for American Indian or Alaska Native persons younger than 65 years old unless they have underlying medical conditions that are PPSV23 indications. However, in special situations, public health authorities may recommend PPSV23 for these individuals aged 50 through 64 years who are living in areas in which the risk of invasive pneumococcal disease is increased.

The full ACIP recommendations may be found at the following address:

For additional questions regarding this memo, please contact your health service region, local health department, or TVFC consultant.